Home
/ Samumed
/ Competitors

Samumed Competitors and Similar CompaniesClear all

Samumed's competitors and similar companies include Roivant Sciences, AdAlta, Vertex Pharmaceuticals and BioMarin Pharmaceutical.

	Samumed Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation.	Roivant Sciences Roivant Sciences is a company that develops and commercializes medicines.	AdAlta AdAlta is a drug discovery and development company intended to generate a new class of protein therapeutics, known as i-bodies.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	BioMarin Pharmaceutical BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.
Founding Date	Founding Date 2008	Founding Date 2014	Founding Date 2006	Founding Date 1989	Founding Date 1997
Type	Type Private	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development healthtech pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations San Diego, US HQ San Diego, US	Locations London, GB HQ Basel, CH Boston, US New York, US	Locations Bundoora, AU HQ Melbourne, AU	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations San Rafael, US HQ Martínez, AR Crows Nest, AU Sao Paulo, BR Bogotá, CO Kronberg Im Taunus, DE Wanchai, HK see more
Employees	Employees 1701% increase	Employees 908	Employees 9	Employees 5,40013% increase	Employees 3,0015% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 8.8 b	Valuation ($) 7.2 m	Valuation ($) 121.4 b	Valuation ($) 13.3 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $8.3m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $12b (FY, 2025)	Revenue (est.) $3.2b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $1.7b (FY, 2025)	Cost of goods $717.4m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $677k (FY, 2025)	Gross profit $10.4b (FY, 2025)	Gross profit $2.5b (FY, 2025)
Net income	Net income N/A	Net income ($397.9m) (FY, 2025)	Net income ($4.5m) (FY, 2025)	Net income N/A	Net income $348.9m (FY, 2025)
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 1 (Q2, 2021)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)
Funding
Total funding raised	Total funding raised $ 438m	Total funding raised $ 1.9b	Total funding raised $ 3m	Total funding raised $ 2.4m	Total funding raised N/A